Portage Non Current Liabilities Total from 2010 to 2024
| PRTG Stock | USD 8.87 5.62 172.92% |
Non Current Liabilities Total | First Reported 2000-12-31 | Previous Quarter 422 K | Current Value 1.1 M | Quarterly Volatility 10.6 M |
Check Portage Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Portage Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 51.3 K, Other Operating Expenses of 19.2 M or Total Operating Expenses of 19.1 M, as well as many indicators such as Price To Sales Ratio of 2 K, Dividend Yield of 0.0 or PTB Ratio of 53.14. Portage financial statements analysis is a perfect complement when working with Portage Biotech Valuation or Volatility modules.
Portage | Non Current Liabilities Total |
Latest Portage Biotech's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Portage Biotech over the last few years. It is Portage Biotech's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Portage Biotech's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Portage Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 8,549,015 | |
| Geometric Mean | 1,372,676 | |
| Coefficient Of Variation | 137.85 | |
| Mean Deviation | 10,659,723 | |
| Median | 620,560 | |
| Standard Deviation | 11,784,765 | |
| Sample Variance | 138.9T | |
| Range | 28.4M | |
| R-Value | 0.52 | |
| Mean Square Error | 109.9T | |
| R-Squared | 0.27 | |
| Significance | 0.05 | |
| Slope | 1,357,105 | |
| Total Sum of Squares | 1944.3T |
Portage Non Current Liabilities Total History
About Portage Biotech Financial Statements
Portage Biotech stakeholders use historical fundamental indicators, such as Portage Biotech's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Portage Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Portage Biotech's assets and liabilities are reflected in the revenues and expenses on Portage Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Portage Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 1.6 M | 1.5 M |
Currently Active Assets on Macroaxis
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:Check out the analysis of Portage Biotech Correlation against competitors. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (68.17) | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.